Alto Neuroscience, Inc. (ANRO)
NYSE:ANRO
Want to see ANRO full AI Analyst Report?
ANRO Stock Chart & Stats
$27.72
-$0.09(-1.99%)
At close: 4:00 PM EST
$27.72
-$0.09(-1.99%)
Day’s Range― - ―
52-Week Range$2.12 - $28.44
Previous CloseN/A
Volume104.17K
Average Volume (3M)2.30M
Market Cap
$817.49M
Enterprise Value$715.11M
Total Cash (Recent Filing)$176.48M
Total Debt (Recent Filing)$23.96M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
May 20, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding31,945,517
10 Day Avg. Volume557,199
30 Day Avg. Volume2,303,174
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)3.40
Price to Sales (P/S)0.00
P/FCF Ratio-9.92
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.21K
Enterprise Value/Ebitda-11.60
Forecast
1Y Price Target
$34.88Price Target Upside25.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Dosing And Tolerability InnovationALTO-207 combines pramipexole with ondansetron to reduce nausea and enable higher tolerated dosing, potentially unlocking stronger antidepressant benefit than pramipexole alone.
Encouraging Clinical SignalsALTO-207 demonstrated promising clinical signals in treatment-resistant depression, including meaningful improvement in anhedonia, indicating the program could drive substantial upside if replicated in pivotal trials.
Funding And Development RunwayPrivate financing was secured to support ALTO-207 through late-stage studies and a potential regulatory submission, reducing near-term funding risk for the program.
Bears Say
ALTO-101 Clinical FailureALTO-101 failed to meet its primary EEG and cognitive endpoints in a Phase 2 study, prompting plans not to advance the program without a partner and reducing near-term catalyst visibility.
Biomarker And Regulatory RiskBiomarker-driven patient selection remains experimental and may not gain regulatory acceptance or broad commercial adoption, increasing the risk of clinical setbacks and potential future equity raises.
Pramipexole Tolerability ConstraintsPramipexole's historical side effects and requirement for slow titration have limited real-world use and could constrain commercial uptake even if tolerability is improved.
Alto Neuroscience, Inc. News
ANRO FAQ
What was Alto Neuroscience, Inc.’s price range in the past 12 months?
Alto Neuroscience, Inc. lowest stock price was $2.12 and its highest was $28.44 in the past 12 months.
What is Alto Neuroscience, Inc.’s market cap?
Alto Neuroscience, Inc.’s market cap is $817.49M.
When is Alto Neuroscience, Inc.’s upcoming earnings report date?
Alto Neuroscience, Inc.’s upcoming earnings report date is May 20, 2026 which is in 27 days.
How were Alto Neuroscience, Inc.’s earnings last quarter?
Alto Neuroscience, Inc. released its earnings results on Mar 16, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.531 by $0.071.
Is Alto Neuroscience, Inc. overvalued?
According to Wall Street analysts Alto Neuroscience, Inc.’s price is currently Undervalued.
Does Alto Neuroscience, Inc. pay dividends?
Alto Neuroscience, Inc. does not currently pay dividends.
What is Alto Neuroscience, Inc.’s EPS estimate?
Alto Neuroscience, Inc.’s EPS estimate is -0.54.
How many shares outstanding does Alto Neuroscience, Inc. have?
Alto Neuroscience, Inc. has 31,945,517 shares outstanding.
What happened to Alto Neuroscience, Inc.’s price movement after its last earnings report?
Alto Neuroscience, Inc. reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.531. Following the earnings report the stock price went up 9.119%.
Which hedge fund is a major shareholder of Alto Neuroscience, Inc.?
Currently, no hedge funds are holding shares in ANRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alto Neuroscience, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.88 (25.81% Upside)
$34.88 (25.81% Upside)
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.1%
Last 30 Days ▲ 15.2%
Last 30 Days ▲ 15.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-57.39%
12-Months-Change
Fundamentals
Return on Equity
-45.01%
Trailing 12-Months
Asset Growth
-20.01%
Trailing 12-Months
Company Description
Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.
ANRO Stock 12 Month Forecast
Average Price Target
$34.88
▲(25.81% Upside)
Technical Analysis
―
Corbus Pharmaceuticals
―
Forte Biosciences
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Ownership Overview
6.38% Insiders
6.10% Mutual Funds
48.63% Other Institutional Investors
33.75% Public Companies and
Individual Investors